1. Methotrexate 20 mg once weekly resulted in significant pain reduction among patients with hand osteoarthritis of the inflammatory phenotype. 2. Adverse events in the treatment group were comparable to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Hand osteoarthritis is a debilitating condition with limited treatment options. Topical therapy, oral analgesics, and non-pharmacological therapy
1. Methotrexate 20 mg once weekly resulted in significant pain reduction among patients with hand osteoarthritis of the inflammatory phenotype. 2. Adverse events in the treatment group were comparable to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Hand osteoarthritis is a debilitating condition with limited treatment options. Topical therapy, oral analgesics, and
ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab)...